Telix Pharmaceuticals Ltd — Capital/Financing Update 2021

Apr 26, 2021

Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401, 55 Flemington Road North Melbourne Victoria, 3051 Australia

==> picture [146 x 81] intentionally omitted <==

Telix Pharmaceuticals and Global Medical Solutions Complete Strategic Manufacturing Agreement

Melbourne (Australia) and Henderson, NV (U.S.A.) – 27 April 2021 . Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed a strategic manufacturing agreement with Global Medical Solutions, Ltd. (GMS), a global manufacturer and distributor of diagnostic and therapeutic radiopharmaceuticals, to manufacture and supply finished unit doses of Telix’s Molecularly Targeted Radiation (MTR) products for certain clinical development programs.

Under the terms of the agreement, GMS will initially manufacture and deliver finished unit doses of Telix’s investigational prostate cancer therapy products TLX591 ([177] Lu-rosopatamab) and TLX592 to sites in Australia for Telix’s planned ProstACT Phase III and CUPID Phase I clinical trials, respectively. The agreement is structured to support Telix’s manufacturing needs for further products and incorporates potential future product distribution requirements in the Asia-Pacific region.

Telix Chief Executive Officer Dr. Christian Behrenbruch stated, “GMS is a dynamic nuclear medicine company with a well-deserved reputation for manufacturing diagnostic and therapeutic radiopharmaceutical agents to rigorous quality standards. We are pleased to have entered this manufacturing partnership with GMS, which supports both our immediate clinical development activities in Australia as we commence key clinical trials. Our agreement also paves the way for a longer-term product relationship within the region, particularly in ASEAN countries where GMS is strongly positioned in terms of regulatory expertise and market access.”

GMS Senior Vice President Operations and Business Development Shahe Bagerdjian said, “Telix has quickly grown into a global theranostics leader with an impressive pipeline of investigational products. We look forward to leveraging our strengths in manufacturing and distribution to support Telix’s development of their lead prostate cancer therapy candidates in these important clinical trials in Australia. GMS is committed to expanding access to diagnostic and therapeutic radionuclides in Australia and more broadly in the Asia-Pacific region. We are well placed to support Telix to develop and ultimately deliver these products to patients with prostate cancer in need.”

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter @TelixPharma and LinkedIn.

Telix’s lead investigational product, Illuccix[®] (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,[1] and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).[2] Telix is also progressing marketing authorisation applications for Illuccix[®] in the European Union[3] and Canada.[4] None of Telix’s products have received a marketing authorisation in any jurisdiction.

1 ASX disclosure 24/11/20.

2 ASX disclosure 14/04/21.

3 ASX disclosure 1/05/20.

4 ASX disclosure 16/12/20.

Page 1

About Global Medical Solutions, Ltd.

Global Medical Solutions, Ltd. (GMS) is a leading-edge operator of centralized radiopharmacies, and manufacturer and distributor of diagnostic and therapeutic radiopharmaceuticals and related equipment, accessories, and services. GMS has businesses in Armenia, Australia, Brazil, China, Hong Kong, Macau, Myanmar, New Zealand, Philippines, Russia, Taiwan, Thailand, and Vietnam, and distributes products to over 25 countries. GMS’s diversified and vertically integrated businesses include SPECT radiopharmacies, PET cyclotron pharmacies, Iodine-131 manufacturing centers, cold kit manufacturing plants, medical device manufacturing plants, nuclear medicine imaging centers, radiology products and equipment, and engineering services. For more information visit www.globalmedicalsolutions.com and follow GMS on LinkedIn.

Telix Corporate Contact

Telix Investor Relations

Dr. Christian Behrenbruch Dr. David N. Cade Telix Pharmaceuticals Limited Telix Pharmaceuticals Limited CEO CBO and Head of Investor Relations Email: chris.behrenbruch@telixpharma.com Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

Page 2